Early detection of breast cancer saves thousands of lives each year. But screening for breast cancer also produces false alarms, which can cause undue stress and costly medical bills. Now, a recent study using patient blood reveals a possible way to reduce the number of false alarms that arise during early screening. Researchers found a panel of proteins shed by breast cancer that are easily detected and can distinguish between real cancer and benign lumps.
This study used diagnostic tools that are already in use in clinics. If the results can be replicated with more volunteers and over a longer period of time, the transition from research lab to clinical lab would be straightforward.
"We were surprised to see we could distinguish between accurate and false results produced by cancer screens such as mammograms," said Department of Energy's Pacific Northwest National Laboratory biologist Richard Zangar, who led the study published in the July issue of Cancer Epidemiology, Biomarkers & Prevention. "We really want to expand the work to verify our findings."
Finding breast cancer is the first step to treating it, but mammograms have a high rate of false alarms. Many women go through unneeded, invasive follow-up tests. To improve the process, some researchers are working on a simple clinical blood test that would detect proteins shed by cancerous tissues.
Called biomarkers, these proteins aren't doing much better than mammograms when it comes to false positives in experimental studies. But researchers have been approaching biomarkers as if every type of breast cancer is the same. In reality, breast cancer exists as several subtypes, with each subtype having distinct characteristics.
For example, breast cancers that produce proteins called estrogen receptors are a different subtype from ones that don't and respond to different therapies. Zangar and colleagues wondered if looking for biomarkers specific for different subtypes would improve the odds of getting the diagnosis right.
To explore this idea, Zangar and his colleagues at PNNL and Duke University picked 23 candidate biomarkers and measured them using tests similar to the ones found in clinics. The team compared proteins in blood from four groups of women — about 20 women in each of the four subtypes of breast cancer — to women with benign lumps that had previously been identified as false positives. Then, Zangar's team homed in on a handful of biomarkers for each subtype that could best distinguish between the most true positives and the least false positives.
The biomarker panel for each subtype was significantly better at distinguishing between breast cancer and benign lumps than mammograms or single biomarkers. The statistical test the team used rates performance from 0.5 to 1.0 — with 0.5 indicating the biomarker panel predicts cancer randomly and 1.0 means it's perfect. Mammograms and the best single biomarkers rank around 0.8. But for two of the most common breast cancer subtypes, the biomarker panels ranked above 0.95 and reached 0.99 depending on which proteins were included in the panel.
"Perhaps researchers haven't found good biomarkers because they've been treating the different subtypes as a single disease, but they actually represent unique diseases that are associated with different biomarkers," said Zangar. "We're hopeful these results can be repeated because these assays would markedly improve our ability to detect breast cancer early on, when treatment is more effective, less costly and less harsh."
In addition, the study hints about the underlying biology of breast cancer. Four of the biomarkers are proteins involved in normal breast development that turn on and off at different times during growth. The fact that these proteins show up in different ways, depending on the subtype of breast cancer, might provide clues about what goes wrong when breast tissue turns cancerous.
The team is seeking additional funding to repeat the study in larger groups of women and to follow volunteers for several years.
Reference: Rachel M Gonzalez, Don S. Daly, Ruimin Tan, Jeffrey R Marks, and Richard C Zangar, Plasma Biomarker Profiles Differ Depending on Breast Cancer Subtype but RANTES Is Consistently Increased, Cancer Epidemiology, Biomarkers & Prevention, July 2011, DOI 10.1158/1055-9965.EPI-10-1248 (http://cebp.aacrjournals.org/content/early/2011/05/16/1055-9965.EPI-10-1248.short).
This work was supported by the Early Detection Research Network of the National Cancer Institute.
Mary Beckman | EurekAlert!
New photocatalyst speeds up the conversion of carbon dioxide into chemical resources
29.05.2017 | DGIST (Daegu Gyeongbuk Institute of Science and Technology)
Copper hydroxide nanoparticles provide protection against toxic oxygen radicals in cigarette smoke
29.05.2017 | Johannes Gutenberg-Universität Mainz
The world's highest gain high power laser amplifier - by many orders of magnitude - has been developed in research led at the University of Strathclyde.
The researchers demonstrated the feasibility of using plasma to amplify short laser pulses of picojoule-level energy up to 100 millijoules, which is a 'gain'...
Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.
Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....
Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.
The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....
An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.
We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...
Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.
Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...
24.05.2017 | Event News
23.05.2017 | Event News
22.05.2017 | Event News
29.05.2017 | Earth Sciences
29.05.2017 | Life Sciences
29.05.2017 | Physics and Astronomy